Generate Biomedicines Inc. Common Stock (GENB)
Stock · NASDAQ · Health Care
$12.07as of 10/16/2026
Price chart
Active signals
Resistance level
$13.41
Industry
Biotechnology: Pharmaceutical Preparations
About GENB
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 312
- Website
- generatebiomedicines.com
Fundamentals
- 1-day range
- $12.43$13.16
- Market cap
- $1.78B
- P/E (trailing)
- —
- P/E (forward)
- -5.73
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- 0.48
- Avg. volume
- 1.09M
52-week range
$11$22.67
Next earnings: November 5, 2026 · EPS estimate $-0.58
Forecasts
5 analyst ratings
Buy 92%
Hold 8%
Sell 0%
1-year price forecast
High
$30
+148.7%
Median
$27
+123.8%
Low
$22
+82.3%
Generate Biomedicines Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- GENBGenerate Biomedicines Inc. Common Stock$12.09▼ 7.43%Market cap $1.78BP/E —$11$22.67
- SEPNSepterna Inc. Common Stock$36.35▼ 2.94%Market cap $1.78BP/E —$17.55$51.1
- KARDKardigan Inc. Common Stock$13.03▼ 6.12%Market cap $1.79BP/E —$12.23$27
- SRPTSarepta Therapeutics Inc. Common Stock (DE)$17.1▼ 3.88%Market cap $1.77BP/E —$14.68$24.68
- SNDXSyndax Pharmaceuticals Inc. Common Stock$12.9▼ 5.49%Market cap $1.76BP/E —$12.99$25.59
- BCAXBicara Therapeutics Inc. Common Stock$16.78▼ 4.77%Market cap $1.81BP/E —$13.7$30.99
- PRGOPerrigo Company plc Ordinary Shares$16.63▲ 0.91%Market cap $1.74BP/E —$9.23$22.02
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GENB Generate Biomedicines Inc. Common Stock | $1.78B | — | $12.09 | ▼ 7.43% | $11$22.67 |
| SEPN Septerna Inc. Common Stock | $1.78B | — | $36.35 | ▼ 2.94% | $17.55$51.1 |
| KARD Kardigan Inc. Common Stock | $1.79B | — | $13.03 | ▼ 6.12% | $12.23$27 |
| SRPT Sarepta Therapeutics Inc. Common Stock (DE) | $1.77B | — | $17.1 | ▼ 3.88% | $14.68$24.68 |
| SNDX Syndax Pharmaceuticals Inc. Common Stock | $1.76B | — | $12.9 | ▼ 5.49% | $12.99$25.59 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.81B | — | $16.78 | ▼ 4.77% | $13.7$30.99 |
| PRGO Perrigo Company plc Ordinary Shares | $1.74B | — | $16.63 | ▲ 0.91% | $9.23$22.02 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Marketbenzinga · 10/14/2026
- Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian CancerYahoo · 10/1/2026
- Roswell Park And Generate Biomedicines Announce First Patient Dosed In First-In-Human Clinical Trial Evaluating GB-5267, Investigational, Autologous IL-18 Armored CAR T-Cell TherapyBenzinga · 10/1/2026
- Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/14/2026
Insider Activity
Insider Actions →Acquired
0
Disposed
1.0K
- Frances Arnold · September 1, 2026 · Sale1.0K @ $16
Institutional Ownership
March 31, 2026
- Total shares held
- 89.87M
- Total value held
- $1.10B
- Institutional holders
- 55
Top holders this quarter
- Unknown62.67M
- Unknown4.22M
- Unknown4.00M
- Unknown3.59M
- Unknown2.11M
- Unknown1.94M
- Unknown1.72M
- Unknown1.42M
- Unknown1.11M
- Unknown833.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Generate Biomedicines Doses First Patient in GB-5267 CAR T Trial
Generate Biomedicines announced that the first patient has received the investigational GB-5267 therapy in a first‑in‑human trial at Roswell Park. This marks the first dose of the IL‑18 armored CAR‑T cell product and represents a key step toward clinical development. The announcement signals progress in the company’s pipeline and may influence investor perception of its therapeutic potential.
Generate Biomedicines Doses First Patient in GB-5267 CAR T Trial. Generate Biomedicines announced that the first patient has received the investigational GB-5267 therapy in a first‑in‑human trial at Roswell Park. This marks the first dose of the IL‑18 armored CAR‑T cell product and represents a key step toward clinical development. The announcement signals progress in the company’s pipeline and may influence investor perception of its therapeutic potential.